Back to Authors

Murphy, Michael Desmond

Mayo Clinic

Alnylam Pharmaceuticals (United States)

Citations 2

Comparison of Patients with Primary Hyperoxaluria 1 and Late-Stage CKD from the BONAPH1DE Registry and ILLUMINATE-C Lumasiran Trial
Baum, Michelle A. , Ben‐Shalom, Efrat , Belostotsky, Vladimir , Sellier-Leclerc, A.L., Du, W. J. , Kauf, Teresa L., Murphy, Michael Desmond, Groothoff, Jaap W. , Lieske, John C. , Knauf, Felix , Sellier‐Leclerc, Anne‐Laure , Du, Weiming, Callanan, Mary B.

Journal of the American Society of Nephrology | December 1, 2025 | Volume: 36 | Issue: 10S | Pages: No page available

10.1681/asn.2025b26anqr1 Get It

Final 60-Month Efficacy, Safety, and Kidney Stone Outcomes of a Phase 3 Trial of Lumasiran for Primary Hyperoxaluria Type 1 in Infants and Young Children
Sas, David J. , Michael, Mini , Frishberg, Yaacov, Ben‐Shalom, Efrat , Shasha‐Lavsky, Hadas , Sellier-Leclerc, A.L., Hogan, Julien, Du, W. J. , Murphy, Michael Desmond, Kaspar, Cristin , Magen, Daniella , Hayes, Wesley Nathan , Sellier‐Leclerc, Anne‐Laure , Hogan, Julien , Du, Weiming

Journal of the American Society of Nephrology | October 23, 2025 | Volume: 36 | Issue: 10S | Pages: No page available

10.1681/asn.2025v7er7rv3 Get It